1/2-Somatic mosaicism and autism spectrum disorder

Information

  • Research Project
  • 9221376
  • ApplicationId
    9221376
  • Core Project Number
    U01MH106883
  • Full Project Number
    5U01MH106883-03
  • Serial Number
    106883
  • FOA Number
    PAR-14-174
  • Sub Project Id
  • Project Start Date
    5/1/2015 - 9 years ago
  • Project End Date
    1/31/2020 - 4 years ago
  • Program Officer Name
    SENTHIL, GEETHA
  • Budget Start Date
    2/1/2017 - 7 years ago
  • Budget End Date
    1/31/2018 - 6 years ago
  • Fiscal Year
    2017
  • Support Year
    03
  • Suffix
  • Award Notice Date
    1/27/2017 - 7 years ago

1/2-Somatic mosaicism and autism spectrum disorder

? DESCRIPTION (provided by applicant): Somatic mutations are de novo mutations that occur after fertilization. Once a cell has acquired a somatic mutation, all of its progenitors will also carry that mutation. Thus, if a cell acquires a mutation early in embryonic development, the mutation will be carried by many of the cells in the body. However, if the mutation occurs late in development, then only a few cells might carry it. Thus, it is possible to have mutations that only occur in the brain, or a small region of the brain. It has been known for a while that somatic mutations can cause cancer, and recent studies are showing that somatic mutations are associated with neurodevelopmental disorders resembling autism spectrum disorders (ASDs) both in terms of their high de novo mutation rate and in terms of their associated symptoms such as intellectual disability and epilepsy. We hypothesize that somatic mutations represent a significant cause of (ASDs) because of the high rate of de novo mutations associated with ASDs, the importance of somatic mutations in some genes known to cause ASDs, and the importance of somatic mutations in other developmental brain disorders with features that overlap ASDs. The technical and resource limitations that had prevented a systematic study of the role of somatic mutations in ASDs have now been overcome thanks to 1] Next-Generation Sequencing (NGS), which allows for the deep sequencing of genes and their transcripts with the ability to analyze each sequence, and 2] tissue banks that have collected brain specimens from individuals who had ASD. In this collaborative UO1 we will employ complementary approaches to systematically identify and functionally characterize somatic brain mutations associated with ASD. For causative somatic mutations identified in ASD brain, we will use techniques developed in our labs to examine individual brain cells for the presence of somatic mutation. This will provide us with a map of what regions of the brain, and what cells types in the brain carry these somatic mutations. We will also model and functionally characterize ASD- associated brain mutations in induced pluripotent cells and mice. This study could 1] improve the genetic diagnosis of ASD; by assessing the prevalence of somatic mutations as a cause of ASD, 2] provide a paradigm that may apply to other complex neuropsychiatric diseases (such as schizophrenia), and 3] improve our understanding of the mechanisms underlying ASD by creating a map of brain regions and cell types involved in ASD.

IC Name
NATIONAL INSTITUTE OF MENTAL HEALTH
  • Activity
    U01
  • Administering IC
    MH
  • Application Type
    5
  • Direct Cost Amount
    1074514
  • Indirect Cost Amount
    536986
  • Total Cost
    1611500
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    242
  • Ed Inst. Type
  • Funding ICs
    NIMH:1611500\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    ZMH1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    CHILDREN'S HOSPITAL CORPORATION
  • Organization Department
  • Organization DUNS
    076593722
  • Organization City
    BOSTON
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    021155724
  • Organization District
    UNITED STATES